Tags

Type your tag names separated by a space and hit enter

Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
Contraception. 2007 Aug; 76(2):84-90.C

Abstract

PURPOSE

This prospective observational noninterventional study aimed at collecting information on changes in cycle control, dysmenorrhea, androgen-related skin conditions and tolerability in a large cohort of women who switched their oral contraceptive (OC) to 2.0 mg chlormadinone acetate (CMA)/0.03 mg ethinylestradiol (EE) (Belara).

MATERIALS AND METHODS

In a total of 20,897 women who were enrolled in a four-cycle clinical evaluation at 1597 gynecological practices throughout Germany, there are 16,781 women who switched from another contraceptive.

RESULTS

The most frequently mentioned complaint for switching contraceptive was seborrhea/acne (6933/16,781 women; 41.3%). This was followed by cycle irregularities (18.8%), headache (15.9%), breast tension (15.1%), amenorrhea (14.9%), spotting (12.8%) and dysmenorrhea (11.7%). After switching to CMA/EE treatment, these symptoms decreased substantially or even disappeared in a large number of women. The vast majority of study participants scored both tolerability and well-being on CMA/EE intake as 'very good' or 'good'. The results revealed that 13,508 women (80.5%) stated being more satisfied or even much more satisfied on CMA/EE intake compared to their previously used contraceptive; most of them had taken progestins of the nortestosterone type. CMA/EE produced beneficial effects on skin conditions and well-being in OC switchers who experienced dissatisfaction with their previous contraceptive regimen.

CONCLUSION

The results of this observational study support that 2.0 mg CMA/0.03 mg EE is well tolerated, provides a reliable cycle stability and is very effective in diminishing dysmenorrhea and other cycle-related complaints. Women suffering from problems on hormonal contraception received benefit from switching to the progesterone derivative CMA-containing OC.

Authors+Show Affiliations

Grünenthal GmbH, Medical Department, 52099 Aachen, Germany. georg.schramm@grunenthal.deNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17656175

Citation

Schramm, Georg, and Birgit Heckes. "Switching Hormonal Contraceptives to a Chlormadinone Acetate-containing Oral Contraceptive. the Contraceptive Switch Study." Contraception, vol. 76, no. 2, 2007, pp. 84-90.
Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76(2):84-90.
Schramm, G., & Heckes, B. (2007). Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception, 76(2), 84-90.
Schramm G, Heckes B. Switching Hormonal Contraceptives to a Chlormadinone Acetate-containing Oral Contraceptive. the Contraceptive Switch Study. Contraception. 2007;76(2):84-90. PubMed PMID: 17656175.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. AU - Schramm,Georg, AU - Heckes,Birgit, Y1 - 2007/06/11/ PY - 2006/07/05/received PY - 2007/03/30/revised PY - 2007/03/30/accepted PY - 2007/7/28/pubmed PY - 2008/1/4/medline PY - 2007/7/28/entrez SP - 84 EP - 90 JF - Contraception JO - Contraception VL - 76 IS - 2 N2 - PURPOSE: This prospective observational noninterventional study aimed at collecting information on changes in cycle control, dysmenorrhea, androgen-related skin conditions and tolerability in a large cohort of women who switched their oral contraceptive (OC) to 2.0 mg chlormadinone acetate (CMA)/0.03 mg ethinylestradiol (EE) (Belara). MATERIALS AND METHODS: In a total of 20,897 women who were enrolled in a four-cycle clinical evaluation at 1597 gynecological practices throughout Germany, there are 16,781 women who switched from another contraceptive. RESULTS: The most frequently mentioned complaint for switching contraceptive was seborrhea/acne (6933/16,781 women; 41.3%). This was followed by cycle irregularities (18.8%), headache (15.9%), breast tension (15.1%), amenorrhea (14.9%), spotting (12.8%) and dysmenorrhea (11.7%). After switching to CMA/EE treatment, these symptoms decreased substantially or even disappeared in a large number of women. The vast majority of study participants scored both tolerability and well-being on CMA/EE intake as 'very good' or 'good'. The results revealed that 13,508 women (80.5%) stated being more satisfied or even much more satisfied on CMA/EE intake compared to their previously used contraceptive; most of them had taken progestins of the nortestosterone type. CMA/EE produced beneficial effects on skin conditions and well-being in OC switchers who experienced dissatisfaction with their previous contraceptive regimen. CONCLUSION: The results of this observational study support that 2.0 mg CMA/0.03 mg EE is well tolerated, provides a reliable cycle stability and is very effective in diminishing dysmenorrhea and other cycle-related complaints. Women suffering from problems on hormonal contraception received benefit from switching to the progesterone derivative CMA-containing OC. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/17656175/Switching_hormonal_contraceptives_to_a_chlormadinone_acetate_containing_oral_contraceptive__The_Contraceptive_Switch_Study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010-7824(07)00151-5 DB - PRIME DP - Unbound Medicine ER -